MacroGenics Inc. (NASDAQ:MGNX) was down 0.9% during mid-day trading on Tuesday . The company traded as low as $31.42 and last traded at $31.50, with a volume of 119,132 shares trading hands. The stock had previously closed at $31.80.

A number of equities research analysts have recently issued reports on MGNX shares. Wedbush reissued an “outperform” rating and issued a $52.00 target price on shares of MacroGenics in a research report on Wednesday, May 18th. Zacks Investment Research raised MacroGenics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, May 4th. Morgan Stanley reaffirmed a “hold” rating on shares of MacroGenics in a research note on Thursday, May 19th. TheStreet raised MacroGenics from a “sell” rating to a “hold” rating in a research note on Friday, August 5th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $35.00 price target on shares of MacroGenics in a research note on Sunday, May 22nd. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. MacroGenics has an average rating of “Buy” and a consensus target price of $38.71.

The company has a 50-day moving average of $29.55 and a 200 day moving average of $22.88. The firm’s market capitalization is $1.03 billion.

MacroGenics (NASDAQ:MGNX) last announced its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $1.14. The business had revenue of $80.67 million for the quarter, compared to analysts’ expectations of $27.22 million. During the same period in the prior year, the business earned ($0.71) earnings per share. The company’s revenue for the quarter was up 1100.4% compared to the same quarter last year. On average, analysts forecast that MacroGenics Inc. will post ($1.29) EPS for the current year.

In other news, VP Lynn Cilinski sold 5,000 shares of the stock in a transaction on Friday, May 27th. The stock was sold at an average price of $25.00, for a total transaction of $125,000.00. Following the completion of the transaction, the vice president now owns 6,923 shares in the company, valued at approximately $173,075. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Jon Marc Wigginton sold 20,000 shares of the stock in a transaction on Monday, August 1st. The stock was sold at an average price of $30.78, for a total value of $615,600.00. Following the transaction, the senior vice president now owns 20,000 shares of the company’s stock, valued at approximately $615,600. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in MacroGenics stock. Jennison Associates LLC boosted its stake in MacroGenics Inc. (NASDAQ:MGNX) by 0.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 267,408 shares of the biopharmaceutical company’s stock after buying an additional 909 shares during the period. Jennison Associates LLC owned approximately 0.78% of MacroGenics worth $8,282,000 as of its most recent filing with the SEC.

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.